Welcome to our dedicated page for Argan SEC filings (Ticker: AGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Argan, Inc. (NYSE: AGX) is a Delaware corporation whose common stock is listed on the New York Stock Exchange, and it files periodic and current reports with the U.S. Securities and Exchange Commission. This SEC filings page brings together Argan’s Forms 10-K and 10-Q, as well as its frequent Form 8-K current reports, which disclose material events such as financial results, major project contracts and dividend declarations.
In its Form 8-K filings, Argan reports items like quarterly earnings releases under results of operations and financial condition, regular quarterly cash dividend announcements, and significant EPC contract awards received by subsidiaries such as Gemma Power Systems and Atlantic Projects Company. These filings also confirm key corporate details, including Argan’s state of incorporation, the AGX trading symbol and its New York Stock Exchange listing.
For investors and analysts, Argan’s annual reports on Form 10-K and quarterly reports on Form 10-Q provide more comprehensive information on segment performance, project backlog, risk factors and accounting policies, while current reports on Form 8-K highlight specific developments between reporting periods. Filings may also describe how new EPC contracts, full notices to proceed and backlog additions affect the company’s future activity.
On this page, AI-powered tools summarize lengthy SEC documents, highlight the main points from Argan’s 10-K and 10-Q filings, and explain the significance of individual 8-K items, such as dividend changes or large contract awards. Users can also review insider and executive-related filings like Form 4, along with proxy materials, to gain additional insight into Argan’s governance and equity activity.
Richard H. Deily, a former CFO and current officer of Argan, Inc. (AGX), reported transactions on 09/12/2025. The filing shows a sale of 7,802 shares of common stock. After the reported sale, the Form 4 lists the reporting persons remaining direct holdings in common stock attributable to outstanding equity awards: 10,000 shares underlying a 04/12/2020 option, 3,500 from a 04/16/2022 option, 2,500 from a 04/17/2024 option, 4,166 time-based RSUs scheduled to vest on 09/13/2025, and 7,500 of various performance-based RSUs/targets. The filing includes detailed vesting and payout conditions for the PRSUs and EPSRSUs with potential payouts from 0% to 200% depending on performance.
Argan, Inc. disclosed that its Board of Directors has approved a 33% increase in the regular quarterly cash dividend, raising it from $0.375 to $0.50 per common share. This higher dividend will be paid on October 31, 2025 to stockholders who are on record at the close of business on October 23, 2025. The change signals a larger ongoing cash return per share for investors through the company’s quarterly dividend program.
Argan, Inc. reports three reportable business segments and had 15,828,289 shares issued with 13,811,575 shares outstanding at July 31, 2025. The company is evaluating adoption of ASU 2023-09 on income tax disclosures. Approximately 26% of the remaining unrecognized performance obligations at July 31, 2025 are expected to be recognized in fiscal 2026, with the remainder in fiscal 2027–2029. The company has a revolving credit facility of $35.0 million priced at SOFR+1.85% with a $30.0 million accordion and a $25.0 million companion facility for letters of credit. Bonds covering warranty and retention obligations totaled $61.2 million. A $9.7 million letter of credit draw is disputed and included in accounts receivable. The IRS has disallowed R&D credits for fiscal 2021–2022; the company is contesting that finding and filed an insurance claim. Argan repurchased 56,117 shares for approximately $7.0 million during the six months ended July 31, 2025. Significant customer concentration remains in Power Industry Services, with top customers representing notable portions of revenue.
Argan, Inc. filed a current report to note that it has released financial results for the three months ended July 31, 2025. The company issued a press release on September 4, 2025 describing its results of operations and financial condition for this period.
The press release is included as Exhibit 99.1 and is incorporated by reference, while an inline XBRL cover page data file is included as Exhibit 104. The report is signed on behalf of Argan by Joshua S. Baugher, Senior Vice President, Chief Financial Officer and Treasurer.
Charles E. Collins IV, Chief Executive Officer of Argan, Inc. (AGX), reported amended insider transactions on Form 4/A. On 07/29/2025 he exercised 1,500 stock options at $46.35 and sold the same 1,500 shares on the open market at an average price of $241.50, leaving him with 22,506 shares. On 07/31/2025 he exercised 2,735 options at $46.35 and 2,265 options at $43.10, then sold 5,000 shares on the open market at an average price of $245, resulting in 21,006 shares beneficially owned following the reported transactions. The filings list option exercise dates and original grant dates and show the exercises were from options granted 01/11/2019 and 09/12/2019. The Form is signed by Mr. Collins on 08/29/2025.
Argan, Inc. (AGX) – Form 144 insider sale notice
Insider John R. Jeffrey, Jr. has filed to sell up to 2,621 common shares through Charles Schwab on or about 29 Jul 2025. The proposed sale equals roughly 0.02 % of the 13.64 m shares outstanding and carries an aggregate market value of $623,798, implying a per-share price near $238.
The shares derive from two recent equity grants: a time-based restricted stock issuance of 390 shares on 13 Jun 2025 and an option-exercise grant of 7,731 shares on 17 Jan 2025. Over the past three months the same insider sold 5,500 shares on 9 Jun 2025 for gross proceeds of $1.20 m. The filer certifies awareness of no undisclosed adverse information and affirms compliance with Rule 144. No operational, earnings or guidance data are included in this filing.